Company: PTPI
Filing Date: 2025-02-14
Form Type: S-1/A
Source: 0001410578-25-000137
Chunk: 228

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-14
Form: S-1/A
Chunk 228
---
                — | ​ | ​                |      — |
| Less: RSUs forfeited                  | ​ |                — | ​ | ​                |      — |
| Less: RSUs expired/cancelled          | ​ |                — | ​ | ​                |      — |
| Less: RSUs vested                     | ​ |          -40,238 | ​ | ​                | -16.87 |
| RSUs outstanding at December 31, 2023 |   |                — | ​ | $                |      — |

On January 4, 2022, pursuant to a consulting agreement, the Company awarded a grant of options to purchase shares of common stock of the Company at an exercise price of $ per share. The shares of common stock underlying the options vested % upon issuance.

On April 7, 2022, the Company awarded the Directors grants of total RSUs with a stock price of $ per share. The RSUs shall vest % on the anniversary of the date of grant. Also on April 7, 2022, Tania King, an employee of Juggernaut Capital Partners LLP, pursuant to her contract, was granted RSUs with a stock price of $ per share. The RSUs shall vest 100% on the anniversary of the date of grant. On September 2, 2022, Ms. King RSUs vested.

On April 10, 2023, the Company awarded Directors grants totaling options with an exercise price of $ per share, vesting % on the one-year anniversary of the date of grant. On December 21, 2023, the Company awarded Directors grants totaling options which vest % on April 10, 2024; granted executives and employee options totaling options with an exercise price of $ per share, of which options vesting immediately upon issuance and vesting upon one executive meeting certain Company performance milestones. As of December 31, 2023, management determined it was not probable that these performance milestones will be met. The Company used the Black Scholes valuation method to determine fair value assuming the following: dividend rate of %, implied volatility of %, a weighted-average risk-free interest rate of %, and have a fair value of $ per share.

Stock-based compensation expense recognized for the years ended December 31, 2023, and 2022, was $ and $, respectively, and is recorded in general and administrative expenses in the consolidated statements of operations. As of December 31, 2023, unrecognized stock-based compensation